Filing Flows

Filing Flows › Companies › Neogenomics › Cash flow

Neogenomics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$20.7M in Q3 2026 · −$28.6M over twelve months

Operating cash flow−$8.9M
Capital spending−$11.8M
Free cash flow−$20.7M
Cash conversion cycle85 days

Analysis

In Q3 2026, Neogenomics generated −$8.9M of operating cash flow and spent $11.8M on capital projects, leaving free cash flow of −$20.7M. That is $21.2M less than in Q3 2025 ($570K).

Over the twelve months to Sep 30, 2026, operating cash flow was $4.3M; the largest uses were net borrowing (+) / repaid (−) ($263M), capital spending ($32.9M); besides operations, cash came from other financing ($250M), shares issued ($15.1M); the cash balance fell by $24.9M.

Operating cash flow was −$8.9M against net income of −$7.5M. The largest differences: receivables −$38.0M, depreciation & amortization +$16.2M, stock-based pay +$8.8M.

Its cash conversion cycle was 85 days (receivables 85 + inventory 21 − payables 22).

Free cash flow

Neogenomics: free cash flow by quarterNeogenomics: free cash flow by quarter−$1.8MQ4 2024−$29.8MQ1 2025$14.0MQ2 2025$570KQ3 2025−$6.5MQ4 2025−$13.1MQ1 2026$11.7MQ2 2026−$20.7MQ3 2026
Operating cash flow less capital spending.
Neogenomics: operating cash flow against capital spendingNeogenomics: operating cash flow against capital spendingOperating cash flowCapital spending$9.8M$11.6MQ4 2024−$25.3M$4.5MQ1 2025$20.3M$6.3MQ2 2025$8.9M$8.3MQ3 2025$1.3M$7.9MQ4 2025−$8.1M$5.0MQ1 2026$20.0M$8.2MQ2 2026−$8.9M$11.8MQ3 2026
Latest (Q3 2026): Operating cash flow −$8.9M, Capital spending $11.8M.

Capital allocation, year by year

Neogenomics: where the cash came from (up) and went (down), by fiscal yearNeogenomics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$26.7MFY2021: Shares issued $28.8MFY2021: Capital spending −$64.1MFY2021: Acquisitions −$419M$28.8MFY2021FY2022: Operating cash flow −$66.0MFY2022: Shares issued $22.9MFY2022: Asset sales $12.1MFY2022: Capital spending −$30.9M$35.0MFY2022FY2023: Operating cash flow −$2.0MFY2023: Shares issued $7.6MFY2023: Capital spending −$28.8M$7.6MFY2023FY2024: Operating cash flow $7.0MFY2024: Shares issued $8.2MFY2024: Capital spending −$41.1M$15.3MFY2024FY2025: Operating cash flow $5.2MFY2025: Net borrowing −$201MFY2025: Shares issued $1.3MFY2025: Capital spending −$27.0MFY2025: Acquisitions −$6.5M$6.5MFY2025
Over these 5 years operating cash flow totalled −$82.4M; the largest uses were acquisitions ($426M) and net borrowing ($201M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$139M
Debt$342M
Net debt$203M
Cash runway20 months

Neogenomics is burning cash: its operations consume cash, a free cash flow of −$82.6M a year at the current rate against $139M of cash and investments: a runway of about 20 months before any new financing.

Where the cash came from and went

Neogenomics: sources (+) and uses (−) of cash, Q3 2026Neogenomics: sources (+) and uses (−) of cash, Q3 2026Shares issued$14.0MCapital spending−$11.8MOperating cash flow−$8.9MCash drawn (+) / kept (−)$6.3MNet borrowing (+) / repaid (−)$867KTaxes on employees’ shares−$404KOther investing−$75KOther financing−$7K
Neogenomics: sources (+) and uses (−) of cash, TTM to Q3 2026Neogenomics: sources (+) and uses (−) of cash, TTM to Q3 2026Net borrowing (+) / repaid (−)−$263MOther financing$250MCapital spending−$32.9MCash drawn (+) / kept (−)$24.9MShares issued$15.1MOperating cash flow$4.3MOther investing$1.4M

From profit to cash

Neogenomics: net income to operating cash flow, Q3 2026Neogenomics: net income to operating cash flow, Q3 2026Net income−$7.5MDepreciation & amortization$16.2MStock-based pay$8.8MReceivables−$38.0MInventory$1.6MPayables$4.1MPrepaid and other assets$621KOperating cash flow−$8.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202685212285
Q2 202677241982
Q1 202679252183
Q4 202576252081
Q3 202576272181
Q2 202576281985
Q1 202581271890
Q4 202481251987

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$8.9M−$11.8M—$867K$14.0M$6.3M−$20.7M
Q2 2026$20.0M−$8.2M——$2.1M$604K$11.7M
Q1 2026−$8.1M−$5.0M——−$338K$13.5M−$13.1M
Q4 2025$1.3M−$7.9M——−$1.9M$4.5M−$6.5M
Q3 2025$8.9M−$8.3M−$463K—$836K−$9.4M$570K
Q2 2025$20.3M−$6.3M——$1.3M$191M$14.0M
Q1 2025−$25.3M−$4.5M——$949K$20.8M−$29.8M
Q4 2024$9.8M−$11.6M——$687K−$5.0M−$1.8M

Neogenomics: income statement and cash flow

Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%. The chart follows the revenue to costs, profit and cash.

Neogenomics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.